摘要
目的 评价奈替米星治疗中风合并肺部感染病人的临床效果和安全性。方法 12 0例中风合并肺部感染病人随机分为两组 ,奈替米星组 62例 ,男性 3 4例 ,女性 2 8例 ,年龄 ( 64± 8)岁 ,用硫酸奈替米星葡萄糖注射液 4mg·kg-1·d-1,静脉滴注 ,每天 1次或 2次 ,疗程 7～ 10d。头孢曲松钠组 5 8例 ,男性 3 1例 ,女性 2 7例 ,年龄( 64± 8)岁 ,用头孢曲松钠粉针剂 ( 2 0～ 4 0 ) g/d加入氯化钠注射液 2 5 0ml,静脉滴注 ,每天 1次或 2次 ,疗程 7～10d。结果 两组疗效、细菌清除率和不良反应发生率差异均无显著性 (P >0 0 5 )。结论 奈米替星用于治疗中风合并肺部感染病人疗效确切 。
Objective To evaluate the clinical therapeutic effect and the safety of netilmicin in treating pulmonary infection of apoplectics.Methods One hundred and twenty cases were divided into 2 groups,62 cases (male:34,female:28,age:64±8 a)in netilmicin group,were treated with netilmicin sulfate and glucose injection 4～6 mg·kg -1·d -1,ivgtt,qd or bid;58 cases in ceftriaxone natrium group (male:31,female:27,age:64±8 a), were treated with ceftriaxone natrium (2.0～4.0) g/d added to sodium chloride injection 250 ml ivgtt,1/d or 2/d;the treating time was 7～10 d.Results The healing rate,bactericidal rate,adverse reaction rate have no statistically significant difference(P>0.05).Conclusion The netilmicin is an effective and safe drug for treating pulmonary infection of apoplectics.
出处
《中国药物与临床》
CAS
2003年第2期114-115,共2页
Chinese Remedies & Clinics
